Candesartan Medical Valley
Angiotensin II Receptor Blocker (ARB) for Hypertension and Heart Failure
Candesartan Medical Valley contains the active substance candesartan cilexetil, an angiotensin II receptor blocker (ARB). It is prescribed for the treatment of high blood pressure (hypertension) in adults and children aged 6 years and older, and for the management of heart failure with reduced systolic function when ACE inhibitors are not tolerated. By blocking the effects of angiotensin II, candesartan relaxes blood vessels, lowers blood pressure, and reduces the workload on the heart.
Quick Facts
Key Takeaways
- Candesartan Medical Valley is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure with reduced ejection fraction.
- It works by blocking the AT1 receptor, causing blood vessel relaxation and reduced aldosterone secretion, resulting in lower blood pressure and decreased cardiac workload.
- The medication must not be used during pregnancy as it can cause serious harm to the developing foetus, particularly in the second and third trimesters.
- Common side effects include dizziness, headache, and respiratory infections; patients should have regular monitoring of kidney function and potassium levels.
- Candesartan provides smooth 24-hour blood pressure control with once-daily dosing, with the full antihypertensive effect typically achieved within 4 weeks.
What Is Candesartan Medical Valley and What Is It Used For?
Candesartan Medical Valley contains the active substance candesartan cilexetil, which is a prodrug. After oral administration, it is rapidly converted during absorption from the gastrointestinal tract into the active compound candesartan. This active metabolite belongs to a class of medicines known as angiotensin II receptor blockers (ARBs), also referred to as angiotensin receptor antagonists or sartans.
The renin-angiotensin-aldosterone system (RAAS) plays a central role in regulating blood pressure and fluid balance. Angiotensin II, a powerful vasoconstrictor, is the principal active hormone of this system. When angiotensin II binds to AT1 receptors found in vascular smooth muscle, the adrenal cortex, the kidneys, and the heart, it triggers a cascade of effects including vasoconstriction, aldosterone release, sodium reabsorption, and sympathetic nervous system activation. Candesartan selectively blocks the AT1 receptor with high affinity, preventing these effects and resulting in vasodilation and reduced blood pressure.
Unlike angiotensin-converting enzyme (ACE) inhibitors, which block the formation of angiotensin II, ARBs like candesartan block the action of angiotensin II at its receptor. This means that candesartan inhibits the effects of angiotensin II regardless of its pathway of formation. Notably, ARBs do not inhibit the breakdown of bradykinin, which is why they are associated with a significantly lower incidence of cough compared to ACE inhibitors. This makes candesartan an important alternative for patients who cannot tolerate ACE inhibitors due to persistent cough.
Approved Indications
Candesartan Medical Valley is approved for the following indications based on robust clinical trial evidence:
- Essential hypertension in adults: Used as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers to lower blood pressure and reduce cardiovascular risk.
- Hypertension in children and adolescents aged 6 to <18 years: Candesartan is one of the few ARBs with specific paediatric dosing guidelines and safety data for this age group.
- Heart failure with reduced left ventricular systolic function (ejection fraction ≤40%) in adults: Candesartan is indicated when ACE inhibitors are not tolerated, or as add-on therapy to ACE inhibitors in patients who remain symptomatic despite optimal ACE inhibitor therapy. The landmark CHARM trials demonstrated significant reductions in cardiovascular death and heart failure hospitalisations.
Hypertension is one of the most prevalent chronic conditions worldwide, affecting an estimated 1.28 billion adults globally according to the World Health Organization (WHO). It is a major modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and premature death. Effective blood pressure control with medications such as candesartan significantly reduces the incidence of these cardiovascular events.
What Should You Know Before Taking Candesartan Medical Valley?
Contraindications
Candesartan Medical Valley must not be taken in the following circumstances:
- Hypersensitivity to candesartan cilexetil or any of the excipients in the formulation. Allergic reactions, although rare, can occur and may include angioedema.
- Pregnancy (second and third trimesters): Candesartan is contraindicated due to the risk of foetal toxicity, including renal failure, oligohydramnios, skull ossification defects, and neonatal death. Treatment should not be initiated during pregnancy, and if pregnancy is detected, candesartan should be discontinued immediately.
- Severe hepatic impairment and/or cholestasis: Candesartan is metabolised partially by the liver, and patients with severe liver disease may have significantly elevated drug exposure.
- Concomitant use with aliskiren-containing products in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 ml/min/1.73 m²): Dual RAAS blockade in these populations increases the risk of hyperkalaemia, hypotension, and acute kidney injury, as demonstrated in the ALTITUDE trial.
Do not take Candesartan Medical Valley if you are pregnant or plan to become pregnant. ARBs can cause injury and death to the developing foetus. If you become pregnant while taking this medicine, stop it immediately and contact your healthcare provider. Alternative antihypertensive therapy with an established safety profile in pregnancy should be initiated.
Warnings and Precautions
Special care should be taken with Candesartan Medical Valley in the following situations:
- Renal impairment: Patients with impaired kidney function require careful monitoring of serum creatinine and potassium levels, particularly during the first weeks of treatment. In patients with bilateral renal artery stenosis or stenosis of a solitary kidney, candesartan may cause a significant rise in blood urea nitrogen and serum creatinine.
- Volume depletion or salt depletion: Patients who are volume-depleted (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhoea, or vomiting) may experience symptomatic hypotension when starting candesartan. Volume status should be corrected before initiating treatment, or treatment should be started under close medical supervision.
- Renovascular hypertension: There is an increased risk of severe hypotension and renal insufficiency in patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney.
- Primary hyperaldosteronism: Patients with primary aldosteronism generally do not respond to antihypertensive medicines acting through inhibition of the RAAS system. Candesartan is therefore not recommended in these patients.
- Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy: As with all vasodilators, special care is warranted in patients with haemodynamically significant valvular disease or outflow tract obstruction.
- Hyperkalaemia: Concomitant use with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other agents that may increase potassium levels (such as heparin, trimethoprim, or co-trimoxazole) may lead to elevated serum potassium. Regular monitoring of potassium is recommended.
Pregnancy and Breastfeeding
Pregnancy: Candesartan is contraindicated during pregnancy. Evidence from epidemiological studies and animal studies has shown that ARBs cause foetal and neonatal toxicity. Exposure during the second and third trimesters has been associated with foetotoxicity including reduced renal function, oligohydramnios, delayed skull ossification, and neonatal hypotension, renal failure, and death. If exposure has occurred from the second trimester onwards, ultrasound monitoring of renal function and skull development is recommended. First-trimester exposure should also be avoided; women planning pregnancy should be switched to an alternative antihypertensive with an established safety profile.
Breastfeeding: It is not known whether candesartan is excreted in human breast milk. Candesartan is excreted in the milk of lactating rats. Due to the potential for serious adverse effects on the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue candesartan, taking into account the importance of the drug to the mother. Other antihypertensive agents with better established safety profiles during breastfeeding may be preferred.
Fertility: Based on preclinical data, candesartan is not expected to affect fertility at therapeutic doses. However, the effects on human fertility have not been specifically studied in clinical trials.
How Does Candesartan Medical Valley Interact with Other Drugs?
Drug interactions with candesartan are clinically important because they can alter the safety and efficacy of treatment. Candesartan primarily interacts through pharmacodynamic mechanisms, particularly involving the renin-angiotensin-aldosterone system and renal potassium handling. Understanding these interactions is essential for safe prescribing and patient counselling.
Major Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Lithium | Reversible increases in serum lithium concentrations and toxicity have been reported with concomitant use of ARBs | Monitor serum lithium levels closely; combination should be used with caution |
| Aliskiren | Dual RAAS blockade increases risk of hyperkalaemia, hypotension, and renal impairment | Contraindicated in diabetic patients and those with GFR <60; avoid in all others |
| ACE inhibitors | Dual RAAS blockade with increased risk of hyperkalaemia, hypotension, and syncope | Not recommended; if used in heart failure, requires close monitoring of renal function, potassium, and blood pressure |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Additive risk of hyperkalaemia | Monitor serum potassium frequently; adjust doses as needed |
| NSAIDs (including COX-2 inhibitors) | May attenuate antihypertensive effect; increased risk of renal impairment and hyperkalaemia | Monitor renal function and blood pressure; avoid prolonged concomitant use in at-risk patients |
Minor Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Potassium supplements | Risk of elevated serum potassium | Monitor potassium levels if co-administered |
| Heparin | Heparin may increase potassium levels via aldosterone suppression | Monitor potassium, particularly with prolonged heparin use |
| Trimethoprim / co-trimoxazole | Trimethoprim impairs renal potassium excretion | Monitor potassium levels within first week of concomitant therapy |
| Other antihypertensives | Additive blood pressure-lowering effect | Monitor blood pressure during dose adjustments; generally beneficial in combination therapy |
Candesartan has minimal cytochrome P450 enzyme interactions. It is not significantly metabolised by CYP enzymes and does not inhibit or induce common CYP isoforms (CYP2C9, CYP3A4, CYP2D6). This means the risk of pharmacokinetic drug interactions is low compared to many other cardiovascular medicines. However, pharmacodynamic interactions (especially those affecting potassium homeostasis and renal function) remain clinically relevant.
What Is the Correct Dosage of Candesartan Medical Valley?
Candesartan Medical Valley should be taken once daily, with or without food, at approximately the same time each day. Consistency in timing helps maintain stable blood levels and ensures smooth 24-hour blood pressure control. The 2 mg tablet strength available in this formulation is particularly useful for initial dose titration in heart failure patients and for paediatric dosing, where lower starting doses are required.
Adults — Hypertension
Hypertension Dosing in Adults
- Starting dose: 8 mg once daily
- Usual maintenance dose: 8 mg once daily
- Maximum dose: 32 mg once daily
- Dose adjustment interval: At least 2 weeks between dose increases
- Volume-depleted patients: Consider starting at 4 mg to reduce the risk of first-dose hypotension
- Renal impairment: No dose adjustment necessary for mild to moderate impairment; start at 4 mg in severe impairment (CrCl <15 ml/min) or patients on haemodialysis
- Hepatic impairment: Start at 4 mg in mild-to-moderate hepatic impairment; contraindicated in severe impairment
Adults — Heart Failure
Heart Failure Dosing in Adults
- Starting dose: 4 mg once daily
- Target dose: 32 mg once daily
- Titration: Double the dose at intervals of at least 2 weeks
- Monitoring: Check blood pressure, renal function, and serum potassium at each dose increase
- Note: Candesartan may be used in combination with other heart failure therapies including ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists
Children and Adolescents (6 to <18 years)
Paediatric Hypertension Dosing
- Children <50 kg: Starting dose 4 mg once daily; maximum 16 mg once daily
- Children ≥50 kg: Starting dose 4–8 mg once daily; maximum 32 mg once daily
- Not recommended: For children under 6 years of age or children with GFR <30 ml/min/1.73 m²
Elderly Patients
No initial dose adjustment is required in elderly patients. However, elderly patients may be more susceptible to hypotension, and blood pressure should be monitored carefully during dose titration. Renal function should be assessed before starting treatment and monitored periodically, as age-related decline in kidney function is common. In very elderly patients (over 75 years) or those with impaired renal function, a lower starting dose of 4 mg may be considered.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten dose. Skipping a single dose is unlikely to cause a significant rise in blood pressure, but consistently missing doses will reduce the effectiveness of treatment.
Overdose
Symptoms of overdose are likely to include symptomatic hypotension (excessively low blood pressure), dizziness, and tachycardia (increased heart rate). Bradycardia (slow heart rate) may also occur from parasympathetic stimulation. If symptomatic hypotension occurs, supportive treatment should be initiated. The patient should be placed in a supine position with legs elevated. Intravenous fluids should be administered as needed. Candesartan is not removed by haemodialysis. In case of overdose, seek emergency medical attention immediately.
What Are the Side Effects of Candesartan Medical Valley?
Like all medicines, Candesartan Medical Valley can cause side effects, although not everyone experiences them. The side effect profile differs somewhat between hypertension and heart failure patients, as heart failure patients tend to have more comorbidities and concomitant medications. The following classification uses the standard frequency categories based on clinical trial data and post-marketing surveillance.
Very Common (affects more than 1 in 10 people)
Observed primarily in heart failure patients
- Hyperkalaemia (elevated potassium) — in heart failure patients
- Hypotension (low blood pressure) — in heart failure patients
- Renal function impairment — in heart failure patients, particularly the elderly
Common (affects 1 to 10 in every 100 people)
Frequency: 1/100 to 1/10
- Dizziness and lightheadedness
- Headache
- Respiratory infections (nasopharyngitis, pharyngitis, upper respiratory tract infection)
- Hypotension (in hypertension patients at higher doses)
- Back pain
- Abnormal renal function (in hypertension patients)
Uncommon (affects 1 to 10 in every 1,000 people)
Frequency: 1/1,000 to 1/100
- Nausea
- Elevated liver enzymes (ALT, AST)
- Rash and skin reactions
- Urticaria (hives)
- Pruritus (itching)
- Hyponatraemia (low sodium)
Rare (affects fewer than 1 in 1,000 people)
Frequency: <1/1,000
- Angioedema (swelling of face, lips, tongue, or throat)
- Hepatitis (liver inflammation)
- Abnormal hepatic function / hepatic injury
- Leukopenia (reduced white blood cell count)
- Neutropenia (reduced neutrophil count)
- Agranulocytosis (severely reduced white blood cells)
- Myalgia (muscle pain)
- Arthralgia (joint pain)
In clinical trials for hypertension, the overall incidence of adverse events with candesartan was comparable to placebo, reflecting its generally excellent tolerability profile. Headache, dizziness, and upper respiratory infections were the most commonly reported effects but occurred at similar rates across treatment and placebo groups.
For heart failure patients, the higher frequency of hypotension, renal impairment, and hyperkalaemia reflects the underlying disease and concomitant use of other RAAS inhibitors, diuretics, and aldosterone antagonists. These effects are generally manageable with dose adjustments and careful monitoring.
Seek immediate medical attention if you experience swelling of the face, lips, tongue, or throat (angioedema), as this can become life-threatening. Also contact your doctor promptly if you experience signs of severe hypotension (persistent dizziness, fainting), signs of liver problems (yellowing of skin or eyes, dark urine, persistent nausea), or signs of kidney problems (decreased urine output, swelling of legs and ankles). Report any unusual or persistent side effects to your healthcare provider.
How Should You Store Candesartan Medical Valley?
Proper storage of medications is essential to maintain their effectiveness and safety. Candesartan Medical Valley tablets should be stored under the following conditions:
- Temperature: Store below 30°C (86°F). Do not freeze.
- Moisture protection: Keep in the original blister pack or container to protect from moisture, as candesartan cilexetil is sensitive to humidity.
- Light protection: Store in the original carton to protect from light when not in use.
- Keep out of reach: Store in a location inaccessible to children and pets.
- Expiry date: Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.
Do not dispose of medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental ingestion by others.
What Does Candesartan Medical Valley Contain?
Active Substance
Each Candesartan Medical Valley 2 mg tablet contains 2 mg of candesartan cilexetil as the active ingredient. Candesartan cilexetil is a prodrug that is rapidly and completely converted to the active drug candesartan by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan cilexetil has the chemical formula C33H34N6O6 and a molecular weight of 610.66 g/mol.
Inactive Ingredients (Excipients)
The tablets also contain the following inactive ingredients, which serve various pharmaceutical functions:
- Lactose monohydrate — used as a filler and binder to provide the tablet with appropriate size and consistency
- Maize starch (corn starch) — acts as a disintegrant to help the tablet break apart in the gastrointestinal tract for proper absorption
- Hydroxypropylcellulose — serves as a binder to maintain tablet integrity
- Macrogol 8000 (polyethylene glycol) — used as a plasticiser in the tablet coating
- Magnesium stearate — a lubricant that prevents the tablet from sticking to manufacturing equipment
- Carmellose calcium — a superdisintegrant that aids tablet dissolution
- Iron oxide (yellow or red) — used as a colouring agent in some strength variants
Candesartan Medical Valley tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The amount of lactose in each tablet is small, but patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Frequently Asked Questions About Candesartan Medical Valley
Candesartan Medical Valley is used to treat high blood pressure (hypertension) in adults and children aged 6 years and older. It is also used to treat heart failure with reduced left ventricular systolic function in adults when ACE inhibitors are not tolerated. By lowering blood pressure, it helps reduce the risk of stroke, heart attack, and kidney disease. The medication works by blocking the angiotensin II type 1 (AT1) receptor, causing blood vessel relaxation and reduced fluid retention.
The most common side effects of candesartan in hypertension patients include dizziness, headache, and respiratory infections. In heart failure patients, hypotension (low blood pressure), hyperkalaemia (elevated potassium), and renal impairment are more frequently observed. Most side effects are mild and tend to resolve with continued use. If you experience persistent or bothersome side effects, consult your healthcare provider for advice.
No, candesartan must not be taken during pregnancy. ARBs including candesartan can cause serious harm and death to the developing foetus, particularly during the second and third trimesters. Effects include reduced kidney function, oligohydramnios, skull ossification abnormalities, and neonatal death. If you become pregnant while taking candesartan, stop the medication immediately and consult your doctor. Your doctor will recommend an alternative blood pressure medication that is safe to use during pregnancy.
Candesartan begins to lower blood pressure within 2 hours of the first dose. The maximum blood pressure-lowering effect is generally achieved within 4 weeks of starting treatment at a given dose. Candesartan provides smooth 24-hour blood pressure control with once-daily dosing due to its tight, slow-dissociating binding to the AT1 receptor. It is important to continue taking candesartan regularly, even if you feel well, as high blood pressure often has no symptoms.
Yes, candesartan is frequently combined with other antihypertensive medications. Common combinations include thiazide diuretics (e.g., hydrochlorothiazide) and calcium channel blockers (e.g., amlodipine). However, combining candesartan with ACE inhibitors or aliskiren is generally not recommended due to the increased risk of hypotension, hyperkalaemia, and kidney problems. In heart failure, candesartan may be used alongside beta-blockers, diuretics, and mineralocorticoid receptor antagonists. Always consult your doctor before starting or changing any combination therapy.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for the one you missed. Try to take your medicine at the same time each day to help you remember. If you frequently forget doses, consider setting a daily alarm or using a pill organiser.
References
- European Medicines Agency (EMA). Candesartan cilexetil — Summary of Product Characteristics. Available at: www.ema.europa.eu
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
- McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362(9386):767-771.
- Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet. 2003;362(9386):772-776.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777-781.
- World Health Organization (WHO). Hypertension — Key facts. Updated March 2023. Available at: www.who.int
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2022. Available at: www.nice.org.uk
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127-e248.
- Joint Formulary Committee. British National Formulary (BNF). Candesartan cilexetil. Available at: bnf.nice.org.uk
- Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (ALTITUDE). New England Journal of Medicine. 2012;367(23):2204-2213.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising specialist physicians in cardiology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the ESC, AHA, WHO, and NICE.
iMedic Medical Editorial Team — Specialists in Cardiology, Clinical Pharmacology, and Internal Medicine
iMedic Medical Review Board — Independent panel reviewing all content according to international guidelines and GRADE evidence framework
Our editorial process ensures that all medical information is evidence-based, up-to-date, and clinically accurate. We declare no conflicts of interest and receive no pharmaceutical company sponsorship or advertising revenue. For more information about our team and editorial standards, visit our Medical Team and Editorial Standards pages.